Serum high-mobility-group box 1 as a biomarker and a therapeutic target during respiratory virus infections

mBio

Volumn 9, Issue 2, 2018, Pages

  Patel, Mira C ^a,b   Shirey, Kari Ann ^b   Boukhvalova, Marina S ^a   Vogel, Stefanie N ^b   Blanco, Jorge C G ^a  

^a Sigmovir Biosystems Inc   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; HMGB1; Influenza; Respiratory syncytial virus; Respiratory viruses

Indexed keywords

BIOLOGICAL MARKER; ERITORAN; HIGH MOBILITY GROUP B1 PROTEIN; INFLUENZA VACCINE; DISACCHARIDE; IMMUNOLOGIC FACTOR; SUGAR PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COTTON RAT; DISEASE MARKER; DISEASE SEVERITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HUMAN RHINOVIRUS; INFLUENZA A VIRUS; INFLUENZA B; INFLUENZA B VIRUS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; VIRAL RESPIRATORY TRACT INFECTION; VIRUS REPLICATION; ANIMAL; BLOOD; CHEMISTRY; DISEASE MODEL; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; PICORNAVIRUS INFECTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SERUM; SIGMODONTINAE; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; DISACCHARIDES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HMGB1 PROTEIN; IMMUNOLOGIC FACTORS; ORTHOMYXOVIRIDAE INFECTIONS; PICORNAVIRIDAE INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SERUM; SIGMODONTINAE; SUGAR PHOSPHATES; TREATMENT OUTCOME;

EID: 85046417699     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00246-18     Document Type: Article

References (53)

1. Paules C, Subbarao K. 2017. Influenza. Lancet 390:697-708. https://doi.org/10.1016/S0140-6736(17)30129-0.
2. Ghebrehewet S, MacPherson P, Ho A. 2016. Influenza. BMJ 355:i6258. https://doi.org/10.1136/bmj.i6258.
3. Taubenberger JK, Morens DM. 2006. 1918 influenza: the mother of all pandemics. Emerg Infect Dis 12:15-22.
4. Taubenberger JK, Morens DM. 2008. The pathology of influenza virus infections. Annu Rev Pathol 3:499-522. https://doi.org/10.1146/annurev.pathmechdis.3.121806.154316.
5. Su S, Chaves SS, Perez A, D’Mello T, Kirley PD, Yousey-Hindes K, Farley MM, Harris M, Sharangpani R, Lynfield R, Morin C, Hancock EB, Zansky S, Hollick GE, Fowler B, McDonald-Hamm C, Thomas A, Horan V, Lindegren ML, Schaffner W, Price A, Bandyopadhyay A, Fry AM. 2014. Comparing clinical characteristics between hospitalized adults with laboratoryconfirmed influenza A and B virus infection. Clin Infect Dis 59:252-255. https://doi.org/10.1093/cid/ciu269.
6. Paul Glezen W, Schmier JK, Kuehn CM, Ryan KJ, Oxford J. 2013. The burden of influenza B: a structured literature review. Am J Public Health 103:e43-e51. https://doi.org/10.2105/AJPH.2012.301137.
7. Krammer F, Palese P. 2015. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 14:167-182. https://doi.org/10.1038/ nrd4529.
8. Ray R, Dos Santos G, Buck PO, Claeys C, Matias G, Innis BL, Bekkat-Berkani R. 2017. A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. Hum Vaccin Immunother 13:1640-1652. https://doi.org/10.1080/21645515.2017.1313375.
9. Soema PC, Kompier R, Amorij JP, Kersten GF. 2015. Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm 94:251-263. https://doi.org/10.1016/j.ejpb.2015.05.023.
10. Li TC, Chan MC, Lee N. 2015. Clinical implications of antiviral resistance in influenza. Viruses 7:4929-4944. https://doi.org/10.3390/v7092850.
11. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, Ermolaeva M, Veldhuizen R, Leung YH, Wang H, Liu H, Sun Y, Pasparakis M, Kopf M, Mech C, Bavari S, Peiris JS, Slutsky AS, Akira S, Hultqvist M, Holmdahl R, Nicholls J, Jiang C, Binder CJ, Penninger JM. 2008. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133:235-249. https://doi.org/10.1016/ j.cell.2008.02.043.
12. Nhu QM, Shirey K, Teijaro JR, Farber DL, Netzel-Arnett S, Antalis TM, Fasano A, Vogel SN. 2010. Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol 3:29-39. https://doi.org/10.1038/mi.2009.120.
13. Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, Karp CL, McAlees J, Gioannini TL, Weiss J, Chen WH, Ernst RK, Rossignol DP, Gusovsky F, Blanco JC, Vogel SN. 2013. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 497:498-502. https://doi.org/10.1038/nature12118.
14. Shirey KA, Lai W, Patel MC, Pletneva LM, Pang C, Kurt-Jones E, Lipsky M, Roger T, Calandra T, Tracey KJ, Al-Abed Y, Bowie AG, Fasano A, Dinarello CA, Gusovsky F, Blanco JC, Vogel SN. 2016. Novel strategies for targeting innate immune responses to influenza. Mucosal Immunol 9:1173-1182. https://doi.org/10.1038/mi.2015.141.
15. Yang H, Wang H, Ju Z, Ragab AA, Lundbäck P, Long W, Valdes-Ferrer SI, He M, Pribis JP, Li J, Lu B, Gero D, Szabo C, Antoine DJ, Harris HE, Golenbock DT, Meng J, Roth J, Chavan SS, Andersson U, Billiar TR, Tracey KJ, Al-Abed Y. 2015. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med 212:5-14. https://doi.org/10.1084/jem.2014 1318.
16. Yang H, Wang H, Chavan SS, Andersson U. 2015. High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule. Mol Med 21((Suppl 1)):S6-SS12. https://doi.org/10.2119/molmed.2015.00087.
17. Andersson U, Tracey KJ. 2011. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29:139-162. https://doi.org/10.1146/annurev-immunol-030409-101323.
18. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251. https://doi.org/10.1126/science.285.5425.248.
19. Alleva LM, Budd AC, Clark IA. 2008. Systemic release of high mobility group box 1 protein during severe murine influenza. J Immunol 181:1454-1459. https://doi.org/10.4049/jimmunol.181.2.1454.
20. Kim S, Kim SY, Pribis JP, Lotze M, Mollen KP, Shapiro R, Loughran P, Scott MJ, Billiar TR. 2013. Signaling of high mobility group box 1 (HMGB1) through Toll-like receptor 4 in macrophages requires CD14. Mol Med 19:88-98. https://doi.org/10.2119/molmed.2012.00306.
21. Perrin-Cocon L, Aublin-Gex A, Sestito SE, Shirey KA, Patel MC, André P, Blanco JC, Vogel SN, Peri F, Lotteau V. 2017. TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. Sci Rep 7:40791. https://doi.org/10.1038/srep40791.
22. Ibricevic A, Pekosz A, Walter MJ, Newby C, Battaile JT, Brown EG, Holtzman MJ, Brody SL. 2006. Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J Virol 80:7469-7480. https://doi.org/10.1128/JVI.02677-05.
23. Blanco JC, Pletneva LM, Wan H, Araya Y, Angel M, Oue RO, Sutton TC, Perez DR. 2013. Receptor characterization and susceptibility of cotton rats to avian and 2009 pandemic influenza virus strains. J Virol 87:2036-2045. https://doi.org/10.1128/JVI.00638-12.
24. Ilyushina NA, Khalenkov AM, Seiler JP, Forrest HL, Bovin NV, Marjuki H, Barman S, Webster RG, Webby RJ. 2010. Adaptation of pandemic H1N1 influenza viruses in mice. J Virol 84:8607-8616. https://doi.org/10.1128/ JVI.00159-10.
25. Staeheli P, Grob R, Meier E, Sutcliffe JG, Haller O. 1988. Influenza virussusceptible mice carry Mx genes with a large deletion or a nonsense mutation. Mol Cell Biol 8:4518-4523. https://doi.org/10.1128/MCB.8.10.4518.
26. Bouvier NM, Lowen AC. 2010. Animal models for influenza virus pathogenesis and transmission. Viruses 2:1530-1563. https://doi.org/10.3390/ v20801530.
27. Ottolini MG, Blanco JC, Eichelberger MC, Porter DD, Pletneva L, Richardson JY, Prince GA. 2005. The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. J Gen Virol 86:2823-2830. https://doi.org/10.1099/vir.0.81145-0.
28. Straight TM, Ottolini MG, Prince GA, Eichelberger MC. 2006. Evidence of a cross-protective immune response to influenza A in the cotton rat model. Vaccine 24:6264-6271. https://doi.org/10.1016/j.vaccine.2006.05.092.
29. Yim K, Miles B, Zinsou R, Prince G, Boukhvalova M. 2012. Efficacy of trivalent inactivated influenza vaccines in the cotton rat Sigmodon hispidus model. Vaccine 30:1291-1296. https://doi.org/10.1016/j.vaccine.2011.12.084.
30. Boukhvalova MS, Blanco JC. 2013. The cotton rat Sigmodon hispidus model of respiratory syncytial virus infection. Curr Top Microbiol Immunol 372:347-358. https://doi.org/10.1007/978-3-642-38919-1_17.
31. Blanco JC, Core S, Pletneva LM, March TH, Boukhvalova MS, Kajon AE. 2014. Prophylactic antibody treatment and intramuscular immunization reduce infectious human rhinovirus 16 load in the lower respiratory tract of challenged cotton rats. Trials Vaccinol 3:52-60. https://doi.org/10.1016/j.trivac.2014.02.003.
32. Patel MC, Pletneva LM, Boukhvalova MS, Vogel SN, Kajon AE, Blanco JCG. 2017. Immunization with live human rhinovirus (HRV) 16 induces protection in cotton rats against HRV14 infection. Front Microbiol 8:1646. https://doi.org/10.3389/fmicb.2017.01646.
33. Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. 1978. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 93:771-791.
34. Schaefer L. 2014. Complexity of danger: the diverse nature of damageassociated molecular patterns. J Biol Chem 289:35237-35245. https:// doi.org/10.1074/jbc.R114.619304.
35. Nosaka N, Yashiro M, Yamada M, Fujii Y, Tsukahara H, Liu K, Nishibori M, Matsukawa A, Morishima T. 2015. Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice. Crit Care 19:249. https://doi.org/10.1186/s13054-015-0983-9.
36. Momonaka H, Hasegawa S, Matsushige T, Inoue H, Kajimoto M, Okada S, Nakatsuka K, Morishima T, Ichiyama T. 2014. High mobility group box 1 in patients with 2009 pandemic H1N1 influenza-associated encephalopathy. Brain Dev 36:484-488. https://doi.org/10.1016/j.braindev.2013.07.001.
37. Blanco JC, Boukhvalova MS, Perez DR, Vogel SN, Kajon A. 2014. Modeling human respiratory viral infections in the cotton rat (Sigmodon hispidus). J Antivir Antiretrovir 6:40-42. https://doi.org/10.4172/jaa.1000093.
38. Patel MC, Wang W, Pletneva LM, Rajagopala SV, Tan Y, Hartert TV, Boukhvalova MS, Vogel SN, Das SR, Blanco JC. 2016. Enterovirus D-68 infection, prophylaxis, and vaccination in a novel permissive animal model, the cotton rat (Sigmodon hispidus). PLoS One 11:e0166336. https://doi.org/10.1371/journal.pone.0166336.
39. Irving SA, Patel DC, Kieke BA, Donahue JG, Vandermause MF, Shay DK, Belongia EA. 2012. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004-2005 through 2007-2008. Influenza Other Respir Viruses 6:37-43. https://doi.org/10.1111/j.1750-2659.2011.00263.x.
40. Paddock CD, Liu L, Denison AM, Bartlett JH, Holman RC, Deleon-Carnes M, Emery SL, Drew CP, Shieh WJ, Uyeki TM, Zaki SR. 2012. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J Infect Dis 205:895-905. https://doi.org/10.1093/infdis/jir861.
41. Kawai N, Ikematsu H, Iwaki N, Maeda T, Satoh I, Hirotsu N, Kashiwagi S. 2006. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 43:439-444. https://doi.org/10.1086/505868.
42. Pletneva LM, Haller O, Porter DD, Prince GA, Blanco JC. 2006. Interferoninducible Mx gene expression in cotton rats: cloning, characterization, and expression during influenza viral infection. J Interferon Cytokine Res 26:914-921. https://doi.org/10.1089/jir.2006.26.914.
43. Pletneva LM, Haller O, Porter DD, Prince GA, Blanco JC. 2008. Induction of type I interferons and interferon-inducible Mx genes during respiratory syncytial virus infection and reinfection in cotton rats. J Gen Virol 89:261-270. https://doi.org/10.1099/vir.0.83294-0.
44. Fagone P, Shedlock DJ, Bao H, Kawalekar OU, Yan J, Gupta D, Morrow MP, Patel A, Kobinger GP, Muthumani K, Weiner DB. 2011. Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination. Gene Ther 18:1070-1077. https://doi.org/10.1038/gt.2011.59.
45. Muthumani G, Laddy DJ, Sundaram SG, Fagone P, Shedlock DJ, Kannan S, Wu L, Chung CW, Lankaraman KM, Burns J, Muthumani K, Weiner DB. 2009. Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specific CD8 T cells. Immunology 128:e612-e620. https://doi.org/10.1111/j.1365-2567.2009.03044.x.
46. Mejias A, Dimo B, Suarez NM, Garcia C, Suarez-Arrabal MC, Jartti T, Blankenship D, Jordan-Villegas A, Ardura MI, Xu Z, Banchereau J, Chaussabel D, Ramilo O. 2013. Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. PLoS Med 10:e1001549. https://doi.org/10.1371/journal.pmed.1001549.
47. Sridharan H, Upton JW. 2014. Programmed necrosis in microbial pathogenesis. Trends Microbiol 22:199-207. https://doi.org/10.1016/j.tim.2014.01.005.
48. Qing DY, Conegliano D, Shashaty MG, Seo J, Reilly JP, Worthen GS, Huh D, Meyer NJ, Mangalmurti NS. 2014. Red blood cells induce necroptosis of lung endothelial cells and increase susceptibility to lung inflammation. Am J Respir Crit Care Med 190:1243-1254. https://doi.org/10.1164/ rccm.201406-1095OC.
49. Rodrigue-Gervais IG, Labbé K, Dagenais M, Dupaul-Chicoine J, Champagne C, Morizot A, Skeldon A, Brincks EL, Vidal SM, Griffith TS, Saleh M. 2014. Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival. Cell Host Microbe 15:23-35. https://doi.org/10.1016/j.chom.2013.12.003.
50. Hosakote YM, Brasier AR, Casola A, Garofalo RP, Kurosky A. 2016. Respiratory syncytial virus infection triggers epithelial HMGB1 release as a damage-associated molecular pattern promoting a monocytic inflammatory response. J Virol 90:9618-9631. https://doi.org/10.1128/ JVI.01279-16.
51. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ, Lee JO. 2007. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130:906-917. https://doi.org/10.1016/j.cell.2007.08.002.
52. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, D.C.
53. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am J Hyg 27:493-497.